Company Overview
Tenaya Therapeutics, Inc. operates as a clinical-stage biotechnology firm focused on the discovery, development, and delivery of therapies specifically designed to address heart disease within the United States. The company's primary operational focus is the advancement of its lead product candidate, TN-201, which represents a gene therapy treatment for myosin binding protein C3-associated hypertrophic cardiomyopathy currently undergoing evaluation in Phase 1b/2 clinical trials. This specialized activity places Tenaya within the broader Healthcare sector and the specific Biotechnology industry, where companies typically operate at early-to-mid stages of product commercialization before achieving widespread market penetration. The company currently maintains a market capitalization of $156.76M and employs 70 individuals, reflecting a small-cap profile typical of pre-revenue or early-revenue biotech entities. These valuation and staffing metrics indicate that Tenaya is a resource-intensive entity relying heavily on capital markets to fund its research and development pipeline, as it has not yet generated sufficient sales revenue to support its operations independently.
Financial Health
The company reports a net income of $-90,597,000 and an EBITDA of $-84,895,000 for the trailing twelve months, while revenue figures are not available, suggesting the business is still in a heavy investment phase. The significant gap between the reported net income loss and the EBITDA loss highlights a substantial cost structure driven by non-operating expenses or interest costs that are not covered by current operational earnings. Tenaya generates free cash flow of $-37,358,876, a metric that indicates the company is burning through its cash reserves to finance clinical trials and operational overhead rather than generating positive cash flow from sales. All three reported margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is characteristic of a clinical-stage company with negligible sales revenue relative to its high fixed research and development costs. Despite the negative earnings, the company holds $100.55M in cash against $10.83M in debt, resulting in a debt-to-equity ratio of 8.79 that suggests a highly leveraged balance sheet relative to its equity base. However, the current ratio stands at 6.84, indicating a robust short-term liquidity position where current assets significantly exceed current liabilities. Return on Equity is -83.8% and Return on Assets is -43.7%, metrics that reveal management is currently deploying capital to generate losses rather than positive returns, a standard but risky dynamic for early-stage biotechnology firms.
Valuation Assessment
Valuation metrics for Tenaya include a trailing P/E ratio of N/A and a forward P/E of -1.60, the latter implying that the market anticipates continued negative earnings or that the current price is not supported by traditional earnings multiples. The company's price-to-book ratio is 1.27, indicating that the market values the firm at a slight premium over its net asset book value, a common occurrence for companies with valuable intellectual property that is not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio, which is N/A due to lack of revenue, and the EV/EBITDA of -0.79, further underscore that traditional valuation models are inapplicable due to the absence of profitable operations. The stock has traded within a 52-week range between $0.36 and $2.35, meaning the current price sits at a level that reflects high volatility but remains below the recent peak. The beta value of 3.23 indicates that the stock's price is significantly more volatile than the broader market, moving more than three times as much as the market index during periods of fluctuation.
Growth & Income
Tenaya Therapeutics reports N/A for both revenue growth year-over-year and earnings growth year-over-year, reflecting that the company is currently generating no sales revenue to measure growth against. Since the company is a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders but instead reinvests all available capital and cash reserves into its clinical development programs. This reinvestment strategy is necessary for a clinical-stage entity to advance its gene therapy candidates through regulatory approval processes before any commercial revenue can be realized. Consequently, the overall growth and income profile of Tenaya is defined entirely by its pipeline progression and future commercial potential rather than current financial performance or dividend distributions.